CBD and sleep: what Shannon 2019 found and what it means

Shannon 2019: the primary human evidence

Shannon 2019 is a retrospective case series of 72 adults presenting with anxiety and sleep complaints. Patients received CBD 25–175mg/day (anxiety patients at 25mg; sleep patients at 25–175mg based on clinical assessment). Sleep scores improved in 66.7% of patients within the first month; anxiety scores improved in 79.2%.

Two things to hold clearly: this is a case series, not a placebo-controlled RCT. And the anxiety signal (79.2%) is stronger than the sleep signal (66.7%) — which supports the hypothesis that CBD's sleep benefit is partly mediated through anxiety reduction. Patients whose sleep was disrupted by anxiety showed more consistent improvement than those whose sleep disorder was independent of anxiety.

The Shannon 2019 sleep improvement was not stable over the full observation period — scores fluctuated, with some months showing less improvement than month one. This is consistent with CBD's non-sedative profile: it doesn't produce tolerance and rebound the way benzodiazepines do, but it also doesn't sustain a uniform effect that sedatives can produce.

How CBD actually affects sleep

What CBD is not

CBD does not act on GABA-A receptors — the target of benzodiazepines (Xanax, Valium), Z-drugs (Ambien), and alcohol. Those substances produce sleep by enhancing inhibitory neurotransmission; the result is sedation with suppression of REM sleep and rebound insomnia on cessation. CBD does not work this way. Expecting CBD to "knock you out" like a sleeping pill is a category error about the mechanism.

What CBD does do

• Anxiolytic effects: CBD's partial agonism at 5-HT1A receptors and modulation of the endocannabinoid system reduce anxiety signaling. Anxiety and hyperarousal are the primary drivers of sleep maintenance insomnia — the 3am wake-up that turns into two hours of rumination. Reducing that arousal is CBD's most plausible sleep mechanism.
• Pain reduction: Chronic pain wakes people up. If CBD reduces pain, sleep continuity improves as a downstream effect. This is the pathway most relevant to patients with fibromyalgia, OA, or RA using CBD for sleep.
• REM sleep behavior disorder: Chagas 2014 found CBD reduced REM sleep behavior disorder (RBD) symptoms in Parkinson's patients — a specific condition where the motor inhibition during REM sleep fails. This is a distinct mechanism from general sleep improvement and shouldn't be generalized to all insomnia.

Sleep architecture: what Linares 2019 shows

Linares 2019 tested 150mg, 300mg, and 600mg CBD (or placebo) in healthy volunteers and measured sleep architecture. At 300mg, CBD did not significantly alter sleep architecture — no REM suppression, no distortion of sleep stages. This matters for people concerned that CBD might produce the same distorted sleep quality that alcohol and benzodiazepines do. At therapeutic doses, that risk appears low.

Sleep continuity vs initiation: where the evidence applies

Dosing for sleep

Shannon 2019 used 25mg as the standard starting dose, with upward titration to 175mg for patients with more severe sleep complaints. The general titration protocol applies: start at 25mg, hold 5–7 days, reassess. Take with a fatty meal — Taylor 2018 showed food increases CBD bioavailability 4–5×.

Timing: 1–2 hours before bed is the common patient-reported sweet spot, though no pharmacokinetic data specifically validates this. CBD's Tmax (time to peak plasma concentration) after oral dosing with food is approximately 3–4 hours — meaning a dose taken 1–2 hours before bed is still rising toward peak as you fall asleep.

Linares 2019's inverted-U dose-response reminder applies here too: higher is not better. Some users report that doses above their individual threshold cause mild alertness rather than calm. If you find CBD stimulating at your current dose, try halving it.

Sleep medications and drug interactions

If you're taking prescription sleep medications, CBD's CYP interaction profile matters:

• Benzodiazepines (temazepam, triazolam): CYP3A4 substrates — CBD may raise exposure. See the benzodiazepine interaction page.
• Zolpidem (Ambien): Primarily CYP3A4 — CBD may raise zolpidem exposure; additive CNS effects are also a concern. Tell your prescriber.
• Melatonin: CYP1A2 substrate. CBD has mild CYP1A2 inhibitory activity. At wellness doses, the interaction is unlikely to be clinically significant. Low-dose melatonin (0.5–3mg) with CBD is generally considered low risk.
• SSRIs (prescribed for insomnia): CYP2D6 and CYP2C19 substrates — see the SSRI interaction page.

Sleep in the context of chronic conditions

For people using CBD primarily for a chronic inflammatory or pain condition, sleep improvement is often the first and most consistent benefit reported — even when pain itself doesn't dramatically improve. This is consistent with the mechanism: reducing nocturnal pain and anxiety allows better sleep, which in turn reduces pain sensitivity the next day through the sleep-pain-sleep feedback loop.

If you have fibromyalgia, RA, knee OA, Hashimoto's, or lupus and your sleep is disrupted, the sleep page is relevant to your situation alongside the condition-specific guide. Starting with sleep as a target metric gives you a cleaner 4-week signal than targeting diffuse pain in conditions where disease activity fluctuates.